Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nonclinical safety assessment of epigenetic modulatory drugs: Current status and industry perspective.
Reynolds VL, Butler P, Abernathy MM, Aschenbrenner L, Best DD, Blank J, Crosby M, Custer L, Escobar PA, Kolaja K, Moggs J, Shuey D, Snyder C, Van Vleet T, Zhou J, Hart TK. Reynolds VL, et al. Among authors: hart tk. Regul Toxicol Pharmacol. 2020 Nov;117:104746. doi: 10.1016/j.yrtph.2020.104746. Epub 2020 Sep 8. Regul Toxicol Pharmacol. 2020. PMID: 32911461
Safety evaluation of immunomodulatory biopharmaceuticals: can we improve the predictive value of preclinical studies?
Black LE, Green JD, Rener J, Dayan A, Cavagnaro JA, Spindler P, Bussiere JL, Bouchard P, Inoue T, Thomas PT, Essayan DM, Gillett NA, Hart TK, Hastings K, House RV, Latta D, Liminga U, Treacy G, Wierda D. Black LE, et al. Among authors: hart tk. Hum Exp Toxicol. 2000 Apr;19(4):205-7. doi: 10.1191/096032700678815855. Hum Exp Toxicol. 2000. PMID: 10918508 No abstract available.
Preclinical development of keliximab, a Primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies.
Bugelski PJ, Herzyk DJ, Rehm S, Harmsen AG, Gore EV, Williams DM, Maleeff BE, Badger AM, Truneh A, O'Brien SR, Macia RA, Wier PJ, Morgan DG, Hart TK. Bugelski PJ, et al. Among authors: hart tk. Hum Exp Toxicol. 2000 Apr;19(4):230-43. doi: 10.1191/096032700678815783. Hum Exp Toxicol. 2000. PMID: 10918514
A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.
Mohammad HP, Smitheman KN, Kamat CD, Soong D, Federowicz KE, Van Aller GS, Schneck JL, Carson JD, Liu Y, Butticello M, Bonnette WG, Gorman SA, Degenhardt Y, Bai Y, McCabe MT, Pappalardi MB, Kasparec J, Tian X, McNulty KC, Rouse M, McDevitt P, Ho T, Crouthamel M, Hart TK, Concha NO, McHugh CF, Miller WH, Dhanak D, Tummino PJ, Carpenter CL, Johnson NW, Hann CL, Kruger RG. Mohammad HP, et al. Among authors: hart tk. Cancer Cell. 2015 Jul 13;28(1):57-69. doi: 10.1016/j.ccell.2015.06.002. Cancer Cell. 2015. PMID: 26175415 Free article.
Preclinical safety of recombinant human interleukin-18.
Herzyk DJ, Bugelski PJ, Hart TK, Wier PJ. Herzyk DJ, et al. Among authors: hart tk. Toxicol Pathol. 2003 Sep-Oct;31(5):554-61. doi: 10.1080/01926230390226681. Toxicol Pathol. 2003. PMID: 14692624
61 results